These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 18924057

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
    Gallwitz B.
    Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.
    Herman GA, Stein PP, Thornberry NA, Wagner JA.
    Clin Pharmacol Ther; 2007 May; 81(5):761-7. PubMed ID: 17392725
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ.
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [Abstract] [Full Text] [Related]

  • 7. [The value of incretin based therapies].
    Gallwitz B.
    Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
    [No Abstract] [Full Text] [Related]

  • 8. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N.
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [Abstract] [Full Text] [Related]

  • 9. The role of vildagliptin in the management of type 2 diabetes mellitus.
    Kleppinger EL, Helms K.
    Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
    Pei Z.
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568
    [Abstract] [Full Text] [Related]

  • 13. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA, Gallwitz B.
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [Abstract] [Full Text] [Related]

  • 14. DPP-4 inhibitors in clinical practice.
    Palalau AI, Tahrani AA, Piya MK, Barnett AH.
    Postgrad Med; 2009 Nov; 121(6):70-100. PubMed ID: 19940419
    [Abstract] [Full Text] [Related]

  • 15. Three new drugs for type 2 diabetes.
    Drug Ther Bull; 2008 Jul; 46(7):49-52. PubMed ID: 18603639
    [Abstract] [Full Text] [Related]

  • 16. [Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2].
    Musch A, Heinzl S.
    Med Monatsschr Pharm; 2007 Aug; 30(8):282-6; quiz 287-8. PubMed ID: 17879807
    [No Abstract] [Full Text] [Related]

  • 17. [Pharmacological sheet. Vildagliptin, oral administration (GALVUS)].
    J Pharm Belg; 2009 Jun; (2):64-6. PubMed ID: 19739530
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.
    Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C.
    Vasc Health Risk Manag; 2008 Jun; 4(4):753-68. PubMed ID: 19065993
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.